Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 deucrictibant ER prophylaxis in hereditary angioedema
jRCT2031240696Phase 3Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Deucrictibant arm with Placebo arm (2 arms). Primary endpoint: Time-normalized number of HAE attacks. Started Aug 2025; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031240696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240696.